4D Molecular Therapeutics...

AI Score

XX

Unlock

3.29
-0.13 (-3.80%)
At close: Apr 24, 2025, 2:46 PM
-3.80%
Bid 3.29
Market Cap 152.33M
Revenue (ttm) 37K
Net Income (ttm) -160.87M
EPS (ttm) -2.98
PE Ratio (ttm) -1.1
Forward PE -0.9
Analyst Buy
Ask 3.3
Volume 167,235
Avg. Volume (20D) 838,214
Open 3.49
Previous Close 3.42
Day's Range 3.27 - 3.49
52-Week Range 2.23 - 28.93
Beta 2.88

About FDMT

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; ...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 227
Stock Exchange NASDAQ
Ticker Symbol FDMT
Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $35.5, which is an increase of 979.03% from the latest price.

Stock Forecasts

Next Earnings Release

4D Molecular Therapeutics Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-13.91%
4D Molecular Therapeutics shares are trading lower... Unlock content with Pro Subscription
3 months ago
-13.77%
4D Molecular Therapeutics shares are trading lower after Leerink Partners and Morgan Stanley cut their respective price targets on the stock.